Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today provided an update on recent accomplishments and announced expected 2024 milestones. The Company will present these updates at the 42nd Annual…
Click here to view original post

Advertisement — Advertise with Biotech Networks